Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials.

ABSTRACT:

Background

Tenecteplase (TNK) was found non-inferior to alteplase in recent clinical trials. We aimed to elucidate the efficacy and safety of TNK versus alteplase for acute ischaemic stroke (AIS).

Methods

Systematic literature search and a meta-analysis of phase III clinical trials in ischaemic stroke patients with TNK use were conducted. The primary outcome was excellent functional outcome which was defined as modified Rankin Scale score of 0-1 at 90 days and safety outcomes included symptomatic intracerebral haemorrhage and death at 90 days. We used random-effects model to estimate the pooled risk difference and 95% CI in R package 'Meta'. The included trials were adapted to the non-inferiority analysis with a margin of -4%.

Results

Three trials enrolling 4094 patie

SUBMITTER: Xiong Y 

PROVIDER: S-EPMC11420912 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature